Literature DB >> 8416022

Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder.

A W Goddard1, S W Woods, D E Sholomskas, W K Goodman, D S Charney, G R Heninger.   

Abstract

To assess the effects of the selective serotonin reuptake blocker fluvoxamine on noradrenergic function in patients with panic disorder, an intravenous yohimbine challenge test was administered to eight patients with panic disorder before and after 8 weeks of fluvoxamine treatment and to a parallel group of eight patients treated with placebo. Fluvoxamine treatment reduced yohimbine-induced anxiety while placebo treatment had no effect on this variable. Both fluvoxamine and placebo treatment had little effect on biochemical or physiologic responses to yohimbine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8416022     DOI: 10.1016/0165-1781(93)90036-g

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  5 in total

Review 1.  Animal models of anxiety disorders.

Authors:  Joachim D K Uys; Dan J Stein; Willie M U Daniels; Brian H Harvey
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

2.  Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder.

Authors:  J Shlik; A Aluoja; V Vasar; E Vasar; T Podar; J Bradwejn
Journal:  J Psychiatry Neurosci       Date:  1997-11       Impact factor: 6.186

3.  Modelling anxiety in humans for drug development.

Authors:  Martin Siepmann; Peter Joraschky
Journal:  Curr Neuropharmacol       Date:  2007-03       Impact factor: 7.363

4.  A risk-benefit assessment of pharmacological treatments for panic disorder.

Authors:  J A Bennett; M Moioffer; S P Stanton; M Dwight; P E Keck
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

Review 5.  Experimental panic provocation in healthy man-a translational role in anti-panic drug development?

Authors:  Michael Kellner
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.